Info

🌱 來自: Antibody Drug Conjugates

Sacituzumab govitecan

• Mechanism:
  • Antitrophoblast cell-surface antigen 2 (Trop-2) antibody coupled to topoisomerase 1 inhibitor SN-38;
  • binds to Trop-2 & is internalized so SN-38 can cause DNA damage, apoptosis, & cell death
• Approved indications:
  • Breast cancer,
  • urothelial cancer
• Dosing:
  • 10 mg/kg d 1 & 8 of 21-d cycle;
  • slow infusion if infusion rxn occurs;
  • reduce dose for neutropenia & neutropenic fever;
  • hold dose for grade 3-4 diarrhea, reduce dose for grade 3-4 nausea/vomiting
• PK/PD:
  • T1/2 15.3 h;
  • free SN-38 T1/2 19.7 h
• AEs:
  • Diarrhea,
  • nausea/vomiting,
  • cytopenia,
  • ↓ Ca,
  • ↓ Na,
  • ↑ LFTs,
  • fatigue
• DDI: UGT1A1 substrate